CJC-1295
Grade BUsed in research and off-label protocols to amplify endogenous growth hormone pulses. Often paired with a ghrelin mimetic like Ipamorelin for synergistic GH release.
Mechanism of Action
Modified growth hormone-releasing hormone (GHRH) analogue. With DAC (drug affinity complex), binds albumin to extend half-life, producing sustained pulsatile GH and IGF-1 elevation.
Typical Protocol
Dose
1–2 mg (with DAC)
Frequency
Weekly
Duration
8–12 week cycles
Timing
Evening, fasted
Route
Subcutaneous injection
Half-life
~8 days (with DAC); ~30 min (without DAC)
Educational reference only — not medical advice.
Reported Benefits
- Sustained elevation of GH and IGF-1
- Improved sleep depth (slow-wave sleep)
- Reported body composition improvements
Side Effects
- Water retention
- Numbness/tingling
- Elevated fasting glucose
- Injection site reactions
Contraindications
- Active malignancy
- Diabetic retinopathy
- Pregnancy
Known Interactions
InsulinGH antagonizes insulin; monitor glucose.
CorticosteroidsBlunt GH response.
References
Comparison vs Alternatives
All Peptides →| Attribute | CJC-1295This page | Ipamorelin | Semaglutide |
|---|---|---|---|
| Evidence | Grade B | Grade B | Grade A |
| Category | Growth Hormone | Growth Hormone | Metabolic |
| Best for | Long-acting GHRH analogue | Selective GH secretagogue | GLP-1 receptor agonist |
| Typical dose | 1–2 mg (with DAC) | 200–300 mcg | 0.25 → 2.4 mg |
| Frequency | Weekly | 1–3× daily | Weekly |
| Route | Subcutaneous injection | Subcutaneous injection | Subcutaneous weekly (oral form available) |
| Legal status | Research chemical. Not approved for human therapeutic use. | Research chemical. Not approved for human therapeutic use. | FDA-approved (Ozempic, Wegovy). Prescription required. |
| Action | Current page | View → | View → |